Drug Manufacturers – Other
(ARQL) Company News for January 18, 2012 – Corporate Summary
• Bio technology company ArQule Inc.’s (NASDAQ:ARQL) share prices gained 11.91% to close at $6.67 after the company’s experimental treatment for liver cancer reported a positive outcome in its Phase II trial • Share prices of discount carrier Sprint Airlines...
18Jan2012 | vitalstocks | 0 comments | Continued(TEVA) Teva Pharmaceutical Industries Provides In-Line 2012 Outlook
Teva Pharmaceutical Industries Ltd. (TEVA) recently provided guidance for 2012. The company expects to earn $5.48 and $5.68 per share on total net sales of about $22 billion. Guidance was generally in line with expectations. While the Zacks Consensus Earnings Estimate, prior...
27Dec2011 | vitalstocks | 0 comments | Continued(ISIS) Isis Pharmaceuticals Analyst Downgrades Shares to Neutral
We recently downgraded Isis Pharmaceuticals (ISIS) to Neutral from an Outperform recommendation. Isis Pharma is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies, such as antisense. The company...
30Nov2011 | vitalstocks | 0 comments | Continued(VRTX) Vertex Pharmaceuticals Riding High on Incivek Sales
Vertex Pharmaceuticals Inc. (VRTX) posted robust third quarter 2011 earnings (including stock-based compensation expense) of 56 cents per share, substantially above the Zacks Consensus Estimate of 19 cents and the year-ago loss of 99 cents. Increased revenues from the sale of...
2Nov2011 | vitalstocks | 0 comments | Continued(RDY) Dr. Reddy’s Laboratories Continues to Grow
Dr. Reddy’s Laboratories (RDY) reported second quarter fiscal 2012 earnings per American Depositary Share (ADS) of 40 cents, significantly above the year-ago earnings of 30 cents per ADS. Higher revenues helped boost earnings. Quarter at a Glance The company reported revenues...
28Oct2011 | vitalstocks | 0 comments | Continued(ALXN) Alexion Pharmaceuticals – Bull of the Day
Alexion Pharmaceuticals’ (ALXN) third quarter 2011 adjusted earnings of $0.32 per share breezed past the Zacks Consensus Estimate by $0.09 and the year-ago adjusted earnings by $0.11. Results were driven by increased revenues thanks to a strong performance by Soliris, Alexion’s...
27Oct2011 | vitalstocks | 0 comments | Continued(ALXA) Company News for October 5, 2011 – Corporate Summary
• Drug developer Transcept Pharmaceuticals Inc.’s (NASDAQ:TSPT) shares increased 33.77% to close at $8.08 after the company’s experimental sleep treatment got approved from the regulators • Share prices of General Maritime Corp. (NYSE:GMR) declined 7.35% ...
6Oct2011 | vitalstocks | 0 comments | Continued(OREX) Orexigen Therapeutics Lifeline for Contrave
Orexigen Therapeutics, Inc.‘s (OREX) shares climbed significantly following a meeting with the US Food and Drug Administration’s (FDA) office of new drugs (OND) regarding the development path for its obesity candidate Contrave. Following the OND’s decision, Orexigen...
24Sep2011 | vitalstocks | 0 comments | Continued(NVO) Novo Nordisk Data Presented at European Association for the Study of Diabetes
Novo Nordisk (NVO) recently presented data from two trials of its lead diabetes drug, Victoza, at the European Association for the Study of Diabetes (EASD). The first trial showed that using Victoza at an early stage in diabetes treatment of patients with type II diabetes, who...
19Sep2011 | vitalstocks | 0 comments | Continued(VRTX) Vertex Pharmaceuticals Reports Positive Data
Vertex Pharmaceuticals Inc. (VRTX) reported positive data from a mid-stage trial on VX-509, which is being studied for the treatment of moderate to severe rheumatoid arthritis (RA). The 12-week study, which evaluated four doses of the candidate, met both the primary endpoints. Data...
12Sep2011 | vitalstocks | 0 comments | Continued(SCR) Simcere Drug Cleared in China
Recently, the State Food and Drug Administration (SFDA) of China delivered a boost to Simcere Pharmaceutical Group (SCR) by clearing its drug Iremod, for treating patients suffering from active rheumatoid arthritis (RA). Iremod, developed solely by Simcere, will be the first...
1Sep2011 | vitalstocks | 0 comments | Continued(TEVA) Teva Pharmaceutical Industries Earns Favorable Court Ruling
Teva Pharmaceutical Industries Ltd. (TEVA) recently received a boost with the US District Court for the Southern District of New York issuing a favorable ruling related to the company’s patent infringement lawsuit against Novartis AG (NVS)/Momenta Pharmaceuticals, Inc. (MNTA)...
1Sep2011 | vitalstocks | 0 comments | Continued(SCR) Simcere Pharmaceutical Group Beats on Bottom Line
Simcere Pharmaceutical Group’s (SCR) second quarter 2011 earnings of 21 cents per American Depositary Share (ADS) surpassed the Zacks Consensus Estimate of 13 cents and the year-ago earnings of 10 cents. Increased revenues and lower share count helped boost earnings. Revenues Revenues...
16Aug2011 | vitalstocks | 0 comments | Continued(VRX) Valeant Pharmaceuticals International Beats Expectations – Ups View
Valeant Pharmaceuticals International’s (VRX) second quarter 2011 earnings of 68 cents per share (excluding special items but including stock based compensation expense) beat the Zacks Consensus Estimate by 3 cents and the year-ago earnings by 8 cents per share. Bottom-line...
8Aug2011 | vitalstocks | 0 comments | Continued(AGN) Company News for August 5, 2011 – Corporate Summary
• NRG Energy (NYSE:NRG) posted Q2 EPS of $2.53, clearly beating the Zacks Consensus Estimate of $0.38 per share. Revenues for the quarter rose 6.8% year-over-year to $2.28 billion, which came in lower than the Zacks Consensus Estimate of $2.7 billion • Shares...
5Aug2011 | vitalstocks | 0 comments | Continued(AGN) Allergan Beats – Revisits Guidance
Allergan, Inc.’s (AGN) second quarter 2011 earnings of 96 cents per share inched ahead of the Zacks Consensus Estimate by a penny and surpassed the company’s guidance range of 93 – 95 cents. Earnings increased 12.9% from the year-ago quarter. Revenues Revenues increased...
3Aug2011 | vitalstocks | 0 comments | Continued(VRTX) Vertex Pharmaceuticals Loss Reduced by Incivek
Vertex Pharmaceuticals Inc. (VRTX) posted second quarter 2011 loss (including stock-based compensation expense) of 82 cents per share, narrower than the Zacks Consensus Estimate of 93 cents and the year-ago loss of 83 cents. Increased revenues from the sale of hepatitis C virus...
1Aug2011 | vitalstocks | 0 comments | Continued(RDEA) Ardea Biosciences – Bull of the Day
We are upgrading Ardea Biosciences Inc (RDEA) to Outperform from Neutral due to the promise shown by its lead pipeline candidate lesinurad, which is being developed for treating hyperuricemia and gout. Lesinurad, which has performed well in clinical studies, will target a market...
15Jul2011 | vitalstocks | 0 comments | Continued(RDY) Dr. Reddy’s Laboratories Earns FDA Approval for Generic
Dr. Reddy’s Laboratories (RDY) delivered yet another positive momentum within a week, as the US Food and Drug Administration (FDA) approved fondaparinux sodium injection, the company’s bioequivalent generic version of Arixtra. The drug is currently marketed by GlaxoSmithKline...
14Jul2011 | vitalstocks | 0 comments | Continued(SHPGY) Shire Entangled in Legal Dispute
The legal tussle between Shire (SHPGY), Sandoz, Inc. — the generic arm of Novartis (NVS) and Amneal Pharmaceuticals — intensified with Shire filing a patent infringement case against the two companies relating to Vyvanse. Vyvanse is indicated for treating patients...
7Jul2011 | vitalstocks | 0 comments | Continued(ALXN) Alexion Pharmaceuticals Stands at Neutral
We are maintaining our Neutral stance on Alexion Pharmaceuticals (ALXN) with a target price of $49.00. Alexion Pharma delivered a strong performance in the first quarter of 2011. First quarter earnings (excluding special items but including stock-based compensation) of 23 cents...
6Jul2011 | vitalstocks | 0 comments | Continued(FRX) Forest Laboratories Announces Viibryd Launch
Forest Laboratories, Inc. (FRX) recently announced the launch of Viibryd (vilazodone HCl) tablets in the US. Viibryd, which is approved for the treatment of adults with major depressive disorder, is available at pharmacies across the US. FDA Approval in Jan 2011 Viibryd received...
6Jul2011 | vitalstocks | 0 comments | Continued(NVO) Novo Nordisk Presents Late Stage Degludec Data
Recently, Novo Nordisk (NVO) presented data from late stage trials, which showed that its ultra-long acting insulin Degludec lowered blood glucose levels with significantly reduced risk of hypoglycemia (low blood sugar) versus Sanofi Aventis’(SNY) Lantus in patients with type...
5Jul2011 | vitalstocks | 0 comments | Continued(ENDP) Endo Pharmaceuticals’ Back Pain Drug Disappoints
Endo Pharmaceuticals (ENDP) recently suffered a pipeline setback with its candidate axomadol performing disappointingly in a mid-stage trial (n=236). Top line results from the study revealed that Endo Pharma’s candidate failed to meet the predetermined end points. The randomized,...
5Jul2011 | vitalstocks | 0 comments | Continued(FRX) Forest Laboratories Seeks FDA Nod for COPD Drug
Forest Laboratories, Inc. (FRX) and partner Almirall, S.A. recently announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for their chronic obstructive pulmonary disease (COPD) candidate, aclidinium bromide. Aclidinium bromide is...
1Jul2011 | vitalstocks | 0 comments | Continued(WCRX) Warner Chilcott Announces Change in Leadership of Research & Development Division
Warner Chilcott (WCRX) recently announced that there will be a change at the helm of its research & development (R&D) division from the beginning of next year. The need for change arose following the decision of Warner Chilcott’s incumbent R&D chief, Dr. Fawzi,...
1Jul2011 | vitalstocks | 0 comments | Continued(NVO) Novo Nordisk Presents Diabetes Study Data
Recently, Novo Nordisk (NVO) presented data from two extension studies of its lead diabetes drug Victoza at the American Diabetes Association. Victoza is currently marketed as a once-daily human Glucagon-Like Peptide- 1 (GLP-1) analogue for the treatment of type II diabetes. The...
29Jun2011 | vitalstocks | 0 comments | Continued(SHPGY) Shire to Produce More Replagal
UK-based Shire (SHPGY) recently announced that the European Medicines Agency (EMA) has increased the company’s manufacturing flexibility for Replagal (agalsidase alfa), an enzyme replacement therapy approved for treating Fabry disease. The EMA declared that Replagal can be...
28Jun2011 | vitalstocks | 0 comments | Continued(ENDP) Endo Pharmaceuticals Announces FDA Action Date
Endo Pharmaceuticals (ENDP) recently announced that the US Food and Drug Administration (FDA) has issued a new action date for the new formulation of painkiller Opana ER. The FDA stated that it will review Endo Pharma’s response to the agency’s complete response letter (CRL)...
27Jun2011 | vitalstocks | 0 comments | Continued(SHPGY) Shire’s Firazyr Earns FDA Panel Backing
Recently, the Pulmonary-Allergy Drugs Advisory Committee of the US Food and Drug Administration (FDA) issued a positive opinion and recommended the US approval of Shire’s (SHPGY) Firazyr (icatibant). Shire is looking to get Firazyr approved in the US for treating patients (aged...
26Jun2011 | vitalstocks | 0 comments | Continued